CU20110219A7 - Composiciones y métodos para administración de vacunas contra virus del dengue - Google Patents

Composiciones y métodos para administración de vacunas contra virus del dengue

Info

Publication number
CU20110219A7
CU20110219A7 CU20110219A CU20110219A CU20110219A7 CU 20110219 A7 CU20110219 A7 CU 20110219A7 CU 20110219 A CU20110219 A CU 20110219A CU 20110219 A CU20110219 A CU 20110219A CU 20110219 A7 CU20110219 A7 CU 20110219A7
Authority
CU
Cuba
Prior art keywords
compositions
den
methods
intradermal
administration
Prior art date
Application number
CU20110219A
Other languages
English (en)
Inventor
Joseph N Brewoo
Charalambos D Partidos
Jorge E Osorio
Dan T Stinchcomb
Original Assignee
Inviragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43220488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20110219(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inviragen Inc filed Critical Inviragen Inc
Publication of CU20110219A7 publication Critical patent/CU20110219A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención reporta composiciones y métodos para vacunar a un sujeto contra virus del dengue. En algunas modalidades, las composiciones de vacuna puden ser administradas por introducción intradérmica. En ciertas modalidades, la introducción intradérmica en un sujeto de una vacuna contra el virus de dengue puede incluir uno o más refuerzos intradérmicos después de la vacunación inicial. Otras modalidades incluyen la inyección intradérmica de una composición de vacuna contra el virus del dengue en donde la composición proporciona protección contra dos o más de DEN-1, DEN-2, DEN-3 y DEN-4.
CU20110219A 2009-06-01 2011-11-29 Composiciones y métodos para administración de vacunas contra virus del dengue CU20110219A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18302009P 2009-06-01 2009-06-01

Publications (1)

Publication Number Publication Date
CU20110219A7 true CU20110219A7 (es) 2012-06-21

Family

ID=43220488

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20110219A CU20110219A7 (es) 2009-06-01 2011-11-29 Composiciones y métodos para administración de vacunas contra virus del dengue

Country Status (17)

Country Link
US (2) US9211323B2 (es)
EP (1) EP2438198A4 (es)
JP (2) JP5848243B2 (es)
KR (1) KR101876304B1 (es)
CN (2) CN107913406A (es)
AU (3) AU2010256845B2 (es)
CA (1) CA2763944A1 (es)
CL (1) CL2011003043A1 (es)
CO (1) CO6470882A2 (es)
CU (1) CU20110219A7 (es)
IL (2) IL216706A0 (es)
MX (1) MX343172B (es)
MY (1) MY184428A (es)
NZ (2) NZ618158A (es)
PH (1) PH12016502431A1 (es)
SG (1) SG176299A1 (es)
WO (1) WO2010141386A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN107913406A (zh) 2009-06-01 2018-04-17 武田疫苗公司 施用针对登革病毒的疫苗的组合物和方法
CA2915027A1 (en) * 2012-06-10 2013-12-19 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
EP2931310A4 (en) * 2012-12-14 2016-05-25 Takeda Vaccines Inc COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
SG11201507460PA (en) 2013-03-15 2015-10-29 Takeda Vaccines Inc Compositions and methods for dengue virus chimeric constructs in vaccines
WO2017179017A1 (en) 2016-04-13 2017-10-19 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
WO2019124557A1 (ja) 2017-12-21 2019-06-27 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
BR112021003962A2 (pt) 2018-09-05 2021-05-25 Takeda Vaccines, Inc. dose unitária de vacina contra dengue e sua administração
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE197607T1 (de) * 1991-09-19 2000-12-15 Us Health Chimäre und/oder wachstumgehemmte flaviviren
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
ATE419006T1 (de) * 1999-03-26 2009-01-15 Us Army Multivalenter dengue-virus impfstoff
AU3844101A (en) * 2000-02-16 2001-08-27 Us Health Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
EP2290108B1 (en) 2001-05-22 2014-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
EA015907B1 (ru) * 2004-10-20 2011-12-30 Санофи Пастер Байолоджикс Ко. Рекомбинантный флавивирус и его применение
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US7618393B2 (en) * 2005-05-03 2009-11-17 Pharmajet, Inc. Needle-less injector and method of fluid delivery
KR20080018271A (ko) * 2005-06-17 2008-02-27 사노피 파스퇴르 약독화된 뎅기 혈청형 2 균주
ZA200802176B (en) * 2005-08-10 2009-08-26 Acambis Inc Vaccination against dengue virus infection
AU2006280144B2 (en) * 2005-08-10 2012-06-14 Sanofi Pasteur Biologics, Llc Vaccination against dengue virus infection
US8337860B2 (en) * 2006-08-15 2012-12-25 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Development of dengue virus vaccine components
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2008085288A1 (en) * 2007-01-11 2008-07-17 Sealed Air Corporation (Us) Method of shaping insulation
WO2008157136A1 (en) 2007-06-14 2008-12-24 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Chimeric sle/dengue type 4 antigenic viruses
CN107913406A (zh) * 2009-06-01 2018-04-17 武田疫苗公司 施用针对登革病毒的疫苗的组合物和方法
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus

Also Published As

Publication number Publication date
KR101876304B1 (ko) 2018-07-10
EP2438198A4 (en) 2014-05-14
US20100303860A1 (en) 2010-12-02
IL216706A0 (en) 2012-02-29
US10010600B2 (en) 2018-07-03
NZ597000A (en) 2014-07-25
NZ618158A (en) 2015-05-29
US20160129102A1 (en) 2016-05-12
AU2010256845A1 (en) 2011-12-22
EP2438198A1 (en) 2012-04-11
US9211323B2 (en) 2015-12-15
MX343172B (es) 2016-10-26
JP5848243B2 (ja) 2016-01-27
MX2011012807A (es) 2012-01-30
JP2016033151A (ja) 2016-03-10
CN102449172A (zh) 2012-05-09
SG176299A1 (en) 2012-01-30
AU2019200212A1 (en) 2019-01-31
WO2010141386A1 (en) 2010-12-09
CO6470882A2 (es) 2012-06-29
CA2763944A1 (en) 2010-12-09
JP2012528794A (ja) 2012-11-15
PH12016502431A1 (en) 2019-02-11
AU2016277660A1 (en) 2017-01-12
CN107913406A (zh) 2018-04-17
KR20120027396A (ko) 2012-03-21
IL243204A0 (en) 2016-02-29
AU2010256845B2 (en) 2016-09-22
CL2011003043A1 (es) 2012-07-20
MY184428A (en) 2021-04-01

Similar Documents

Publication Publication Date Title
CU20110219A7 (es) Composiciones y métodos para administración de vacunas contra virus del dengue
BRPI0913012A2 (pt) vírus do nilo ocidental/da dengue quiméricos
AR093421A1 (es) Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4
MX336687B (es) Tratamiento y prevencion de infecciones del virus del dengue.
ECSP14013315A (es) Inhibidores de aplicación viral
UY32457A (es) Vacuna del virus del dengue inactivado
UY33797A (es) Composiciones farmacéuticas para el tratamiento del vhc
PE20140646A1 (es) Vacuna de virus de dengue inactivado
MX338530B (es) Inhibidores de molecula pequeña para el tratamiento o prevencion de infeccion de virus del dengue.
AR064009A1 (es) Metodo de inmunizacion contra los 4 serotipos del dengue
AR095598A1 (es) Composiciones y métodos para construcciones quiméricas del virus del dengue en vacunas
PH12015502230A1 (en) Novel viral replication inhibitors
CO6511253A2 (es) Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
UY32274A (es) Pestivirus quimericos
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
MX2016003323A (es) Derivados de dosoxinojirimicina y sus metodos de uso.
AR101814A1 (es) Partícula de tipo virus flavivirus
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
WO2013012835A3 (en) Sirna useful in the treatment of flavivirus infection
CL2017001595A1 (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
ECSP12012131A (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quiméricos
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
AR082057A1 (es) Vacunas de enterovirus para prevenir o tratar diabetes tipo 1 (i)